BUZZ-J.P.Morgan upgrades Bioventus to 'neutral' on improved growth visibility, execution

Reuters

Dec 18, 2024

** Brokerage J.P.Morgan upgrades medical product maker Bioventus to "neutral" from "underweight", raises PT to $13 from $12

** Notes better visibility into co's growth; says co has taken steps in the right direction to stabilize and restore growth

** Says 2024 marked return to stability for co, with knee-therapy-related headwinds now lapped and fully in rearview and "pockets of strength" in areas including Ultrasonics

** Expects deals, while likely off the table for co in near to midterm future, could get investors confident in driving upside to numbers

** Says M&A has historically been a key factor in co's growth algorithm given its limited organic pipeline

** Also says the significant amount of debt in co's balance sheet could limit more strategic uses of capital

** Two of three brokerages rate the stock "buy", and one "hold"; with a median PT of $15

** Up to last close, stock has gained 112% YTD

(Reporting by Neil J Kanatt in Bengaluru)

((Neil.JKanatt@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2492601879"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492601879\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492601879?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 00:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492601879","market":"us","top_or_hot":-1,"title":"BUZZ-J.P.Morgan upgrades Bioventus to 'neutral' on improved growth visibility, execution","media":"Reuters","content":"<html><body><p>** Brokerage J.P.Morgan upgrades medical product maker Bioventus    to \"neutral\" from \"underweight\", raises PT to $13 from $12</p><p>   ** Notes better visibility into co's growth; says co has taken steps in the right direction to stabilize and restore growth</p><p>   ** Says 2024 marked return to stability for co, with knee-therapy-related headwinds now lapped and fully in rearview and \"pockets of strength\" in areas including Ultrasonics</p><p>   ** Expects deals, while likely off the table for co in near to midterm future, could get investors confident in driving upside to numbers</p><p>   ** Says M&amp;A has historically been a key factor in co's growth algorithm given its limited organic pipeline</p><p>   ** Also says the significant amount of debt in co's balance sheet could limit more strategic uses of capital</p><p>   ** Two of three brokerages rate the stock \"buy\", and one \"hold\"; with a median PT of $15</p><p>   ** Up to last close, stock has gained 112% YTD</p><p> (Reporting by Neil J Kanatt in Bengaluru)</p><p>((Neil.JKanatt@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-J.P.Morgan upgrades Bioventus to 'neutral' on improved growth visibility, execution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-J.P.Morgan upgrades Bioventus to 'neutral' on improved growth visibility, execution\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-18 00:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>** Brokerage J.P.Morgan upgrades medical product maker Bioventus    to \"neutral\" from \"underweight\", raises PT to $13 from $12</p><p>   ** Notes better visibility into co's growth; says co has taken steps in the right direction to stabilize and restore growth</p><p>   ** Says 2024 marked return to stability for co, with knee-therapy-related headwinds now lapped and fully in rearview and \"pockets of strength\" in areas including Ultrasonics</p><p>   ** Expects deals, while likely off the table for co in near to midterm future, could get investors confident in driving upside to numbers</p><p>   ** Says M&amp;A has historically been a key factor in co's growth algorithm given its limited organic pipeline</p><p>   ** Also says the significant amount of debt in co's balance sheet could limit more strategic uses of capital</p><p>   ** Two of three brokerages rate the stock \"buy\", and one \"hold\"; with a median PT of $15</p><p>   ** Up to last close, stock has gained 112% YTD</p><p> (Reporting by Neil J Kanatt in Bengaluru)</p><p>((Neil.JKanatt@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BVS","symbol_name":"Bioventus Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2492601879","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492601879","pubTimestamp":1734454342,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Brokerage J.P.Morgan upgrades medical product maker Bioventus    to \"neutral\" from \"underweight\", raises PT to $13 from $12   ** Notes better visibility into co's growth; says co has taken steps in the right direction to stabilize and restore growth   ** Says 2024 marked return to stability for co, with knee-therapy-related headwinds now lapped and fully in rearview and \"pockets of strength\" in areas including Ultrasonics   ** Expects deals, while likely off the table for co in near to midterm future, could get investors confident in driving upside to numbers   ** Says M&A has historically been a key factor in co's growth algorithm given its limited organic pipeline   ** Also says the significant amount of debt in co's balance sheet could limit more strategic uses of capital   ** Two of three brokerages rate the stock \"buy\", and one \"hold\"; with a median PT of $15   ** Up to last close, stock has gained 112% YTD ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"BVS":"Bioventus Inc."},"translate_title":"BUZZ-摩根大通将Bioventus评级上调至“中性”，以提高增长可见性和执行力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BVS":1},"content_text":"** Brokerage J.P.Morgan upgrades medical product maker Bioventus    to \"neutral\" from \"underweight\", raises PT to $13 from $12   ** Notes better visibility into co's growth; says co has taken steps in the right direction to stabilize and restore growth   ** Says 2024 marked return to stability for co, with knee-therapy-related headwinds now lapped and fully in rearview and \"pockets of strength\" in areas including Ultrasonics   ** Expects deals, while likely off the table for co in near to midterm future, could get investors confident in driving upside to numbers   ** Says M&A has historically been a key factor in co's growth algorithm given its limited organic pipeline   ** Also says the significant amount of debt in co's balance sheet could limit more strategic uses of capital   ** Two of three brokerages rate the stock \"buy\", and one \"hold\"; with a median PT of $15   ** Up to last close, stock has gained 112% YTD (Reporting by Neil J Kanatt in Bengaluru)((Neil.JKanatt@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}